Aidoc's CARE model earns TIME spot for real-time medical alerts

Aidoc's artificial intelligence system, CARE, has been named one of TIME magazine's Best Inventions of 2026 in the Medicine and Health category. The Israeli medical technology firm announced the selection on Saturday, noting that the model helps physicians identify serious conditions at an earlier stage by analyzing medical imaging and clinical text.

The system operates by scanning patient data for potentially urgent findings. When it detects a critical issue, it flags the examination so medical teams can prioritize it for review. This capability allows the company to expand the number of conditions it monitors without developing a separate AI model for each specific disease, according to the company's statement.

TIME's selection panel cited the technology's ability to detect a wide range of potentially serious medical findings as a key factor in its inclusion. The annual list recognizes inventions based on originality, effectiveness, ambition, and impact. Other technologies featured on the 2026 list include Anthropic's Claude Code and Lovable.

Elad Walach, Aidoc's CEO and co-founder, said the selection recognizes a major trend in medical diagnostics. "Medical foundation models that can detect hundreds of diseases and significantly improve diagnostic safety are among the developments that will affect us all," Walach said. "We are rapidly approaching a reality in which AI will serve as an additional pair of eyes in almost every medical diagnosis."

Aidoc's AI solutions have received clearance from the US Food and Drug Administration. The company said its technology is currently used in more than 150 healthcare systems in the United States and over 1,600 hospitals worldwide. Most hospitals in Israel also utilize the platform, the company reported.

Founded in 2016 by Walach, Michael Braginsky, and Guy Reiner, Aidoc has developed a platform that alerts doctors to potentially life-threatening conditions in real time. The company has raised more than $500 million since its founding. Investors include General Catalyst, TLV Partners, Magma Emerge, Square Peg, SoftBank's Vision Fund 2, and NVentures, the venture capital arm of Nvidia.

The most recent funding round, which closed in April 2026, totaled $150 million. Goldman Sachs' growth investment division led that round. Walach described CARE as a significant growth driver for the company and a step toward integrating AI as a standard safeguard in routine medical diagnoses.